乳腺浸润性导管癌组织FOXP3表达及其预后意义

目的 叉头框转录因子P3(forkhead box P3,FOXP3)属于叉头框/翼状螺旋转录因子(forkhead box,FOX)家族成员,早期被认为特异性表达于免疫抑制性CD4+ CD25+调节性T细胞(CD4+ CD25+ regulatory T cell,Treg).而近些年来研究发现,FOXP3在多种肿瘤细胞中均有表达.本研究旨在探讨FOXP3在乳腺浸润性导管癌组织中的表达与临床病理学特征的关系及其预后意义.方法 收集2009 01-01-2012-04-30河北医科大学第四医院乳腺中心收治的123例乳腺浸润性导管癌标本,采用免疫组织化学法检测FOXP3蛋白的表达,分析FOXP3与肿瘤临床病理学特征间的关系,并采用Kaplan-Meier法及Cox比例回归风险模型进行生存分析.结果 FOXP3蛋白在乳腺浸润性导管癌实质细胞质和细胞核中均有表达,FOXP3总表达率为68.29％ (84/123).生存分析结果显示,FOXP3表达阳性组的无病生存率(disease free survival,DFS)为89.29％,高于阴性组的71.79％,差异有统计学意义,x2=6.119,P=0.013;但2组的总生存率(overall survival,OS)差异无统计学意义,x2 =1.911,P=0.167.进一步分析FOXP3在乳腺癌细胞中的表达部位发现,FOXP3在细胞核中表达率为47.97％(59/123),细胞质中为63.41％ (78/123).生存分析结果显示,FOXP3细胞核表达阳性组的OS和DFS分别为94.92％和91.53％,均高于细胞核阴性组的82.81％和76.56％,差异均有统计学意义,x2值分别为5.265和4.974,P值分别为0.022和0.026;且Cox多因素分析结果显示,细胞核FOXP3是改善OS的独立预后因素,HR=0.245,P=0.033;但细胞质FOXP3与预后无明显相关性.在FOXP3细胞核表达阳性患者中,无脉管瘤栓组(x2 =5.117,P=0.024)及Ki-67低表达组(x2 =4.214,P=0.041)的表达率更高;且各分子分型间表达率差异有统计学意义,x2=12.983,P=0.002;在Luminal A型乳腺癌中FOXP3细胞核表达率最高,为68.18％.结论 FOXP3在乳腺浸润性导管癌中的预后意义与表达部位相关,细胞核FOXP3高表达是改善乳腺癌OS的独立预后因素,而细胞质FOXP3的表达意义尚不明确.细胞核FOXP3可作为乳腺癌预后良好的预测指标.     

Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer

The aim of the present study is to augment the prognostic power of breast cancer grading by elaboration of quantitative histopathological methods. We focus on the recently introduced morphometrical grading system in which the three grading sub-features of the WHO grading system are evaluated with the help of computerised nuclear morphometry, and quantitative methods for assessing mitotic activity and tubular differentiation. The prognostic value of the morphometrical grading system is now confirmed in a material of 159 cases of invasive ductal breast cancer. In the current material the morphometrical grading system very efficiently predicted the prognosis of breast cancer by dividing the patients into favourable (grade I), intermediate (grade II), and unfavourable (grade III) outcome (P<0.0001). The morphometrical grading system was especially efficient in identifying patients with the most unfavourable outcome. In our material the morphometrical grade III was associated with a 5.4-fold risk of breast cancer death. In light of the present results, the morphometrical grading can be applied to clinical use as an aid in treatment decisions of patients with invasive ductal breast cancer.     

218例不同分子亚型浸润性乳腺癌患者的临床特征

目的：探讨浸润性乳腺癌分子亚型在中国人群中的分布,以用于判断临床预后和指导治疗。方法：回顾分析218例浸润性乳腺癌患者,根据雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体2（HER2）的水平划分为4个分子亚型。对比分析4型患者的分布比例、发病年龄、病理组织学分类、肿瘤最大径以及淋巴结转移等相关因素。结果：在4型中,luminal A型例数最多,共131例（60.1%）;basal-like型共有63例（28.9%）;luminal B型和HER2过表达型所占比例较少,均为12例（5.5%）。发病年龄以40岁～59岁年龄段发生乳腺癌例数最多,达到77.06%。HER2过表达型在50岁～59岁年龄段发病例数显著增高,与其余3组相比有显著性差异（P〈0.05）。病理分类显示,浸润性导管癌最多,各型之间无显著性差异（P〉0.05）;从淋巴结阳性病例中,HER2过表达型和luminal B型多枚淋巴结转移比例更高（P〈0.05）。肿瘤最大径分析显示,HER2过表达型和basal-like型病例肿瘤最大径2cm～5cm的比例较高,而luminal A型和luminal B型的肿瘤最大径多小于2cm（P〈0.05）。结论：在4型中,luminal A型所占比例最高;HER2过表达型在50岁～59岁年龄段发病较多见;浸润性导管癌是最常见的病理组织类型;HER2过表达型和luminal B型多枚淋巴结转移情况更多发生;HER2过表达型和basal-like型肿瘤较luminal A型更大。     

不同分子亚型的晚期乳腺癌化疗疗效观察

目的：观察不同分子亚型的晚期乳腺癌对多西紫杉醇联合顺铂化疗方案的反应性、疾病进展时间（TTP）及生存时间,进一步评估不同分子亚型乳腺癌的临床特征及预后。方法：利用免疫组化方法将2000年元月至2006年10月收治的62例晚期乳腺癌分为3种分子亚型,62例多西紫杉醇联合顺铂方案化疗,回顾性分析3种亚型乳腺癌的化疗反应性、疾病进展时间及生存期。结果：62例患者中,Basal—like亚型为14例（22．6％）,HER2＋／ER一亚型（16．1％）,Luminal亚型38例（61．3％）。Basal—like亚型有效率为64．3％,HER2＋／ER一亚型为60．0％,Luminal亚型为47．4％（P=0．551）,3者之间无显著性差异。Basal—like亚型,ITI’P为3．2个月,HER2＋／ER一亚型为5．3个月,Luminal亚型为10．1个（P=0．005）,Basal—like亚型生存时间为7．0个月,HER2-4-／ER-亚型为11．3个月,Luminal亚型为19．8个（P=0．004）,3者在TTP及生存时问存在显著性差异。结论：不同分子亚型的晚期乳腺癌对多西紫杉醇联合顺铂化疗方案的反应性相似,但Basal-like亚型和HER2＋／ER-亚型具有较短的疾病进展时间和生存期,Basal-like亚型的预后最差。原因可能主要与它的生物学特征更具侵袭性有关。     

Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast

Background:

Invasive micropapillary carcinoma (IMPC) is a variant of breast carcinoma with a higher propensity for lymph node metastases compared with invasive ductal carcinoma (IDC).

Methods:

Retrospective analysis of 636 IMPC and 297 735 IDC cases in the Surveillance, Epidemiology and End Results database comparing disease-specific survival (DSS) and overall survival (OS) between IMPC and IDC.

Results:

A higher percentage of IMPC cases (52.0%) had nodal metastases compared with IDC cases (34.6%). The 5-year DSS and OS for IMPC was 91.8% and 82.9%, respectively compared with 88.6% and 80.5% for IDC, respectively. For both IMPC and IDC, oestrogen-receptor positivity was associated with better survival, while having four or more positive lymph nodes or larger tumour size correlated with worse survival. Radiotherapy provided a survival benefit for both histological types.

Conclusions:

Despite IMPC''s higher propensity for lymph node metastasis, IMPC has DSS and OS that compare favourably with IDC.     

MTDH在浸润性乳腺癌不同分子亚型中的表达及临床意义

目的：检测MTDH基因在浸润性乳腺癌不同分子亚型中的表达情况,研究MTDH与分子分型的关系及临床意义。方法：通过免疫组化方法检测287例浸润性导管癌癌组织的ER、PR、Ki67、HER－2和MTDH的表达情况。然后分为不同分子亚型,统计分析MTDH在各亚型中的表达情况以及与临床病理因素的相关性。结果：287例浸润性导管癌中,Luminal A型70例,Luminal B型123例,HER－2阳性型47例,Basal －like 型47例。MTDH 总体高表达率为45．99％,亚型中分别为：Luminal A：31．43％,Luminal B：48．78％,HER－2＋：51．06％,Basal－like：55．32％。MTDH高表达与肿瘤大小、脉管浸润、腋窝淋巴结转移及TNM分期相关。结论：MTDH 在Basal－like型浸润性导管癌中高表达,为Basal－like型乳腺癌的治疗提供新的靶基因。     

肿瘤浸润淋巴细胞对不同分子亚型乳腺癌预后效应的研究进展

肿瘤浸润淋巴细胞（tumor infiltrating lymphocytes,TILs）是肿瘤微环境的重要组分,对结肠癌、肺癌等多种肿瘤预后有明确的指示效应。在乳腺癌中,相关研究的结论并不一致。考虑到乳腺癌是一组由多种不同分子亚型组成的异质性疾病,TILs对不同分子亚型乳腺癌的预后指示作用也不同。本综述阐述常用TILs指标对不同分子亚型乳腺癌预后指示效应的相关研究进展。     

不同分子分型乳腺癌患者预后与淋巴结转移率的相关性分析

[摘要] 目的: 探讨不同分子分型乳腺癌患者预后与Ⅱ、Ⅲ期乳腺癌淋巴结转移率的相关性。方法: 回顾性分析2011 年1 月至2016 年1 月在南京医科大学附属常州第二人民医院311 例确诊为Ⅱ、Ⅲ期乳腺癌并首选手术治疗的乳腺癌患者的临床资料,依据雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体-2（HER2）和Ki-67 增殖指数分为Luminal A型、Luminal B 型、HER2 过表达型和三阴型（TNBC）4 型。通过卡方检验分析不同分组间患者的临床特征;通过Kaplan-Meier 生存曲线评估腋淋巴结转移率（LNR）对各型乳腺癌患者预后的影响,以及相同LNR的不同分子分型的乳腺癌预后的差异,通过Spearman 相关分析LNR与Ki-67 增殖指数的相关性。结果: 不同分子分型在患者年龄、绝经情况、肿瘤大小、淋巴结状态及转移部位等临床特征差异无统计学意义（均P>0.05）。LNR为0 或>0.65 的4 组分子分型的无病生存时间（DFS）差异无统计学意义（χ2=3.581、2.808,均P>0.05）,LNR介于0.01~0.65 的4 组分子分型的DFS差异有统计学意义（χ2=24.366、8.169,均P<0.05）。LNR与Ki-67 增殖指数呈正相关（r=0.125,P<0.05）。多因素Cox 回归分析显示,乳腺癌患者预后与分子分型（RR=1.179,95%CI=1.023~1.358;χ2=5.165,P<0.05）、LNR（RR=1.137,95%CI=0.985~0.999;χ2=5.589,P<0.05）及Ki-67 增殖指数（RR=0.992,95%CI=1.022~1.264;χ2=5.623,P<0.05）有关。结论: LNR是Ⅱ、Ⅲ期乳腺癌预后的重要影响因素,相同LNR的不同分子分型预后差异显著,LNR与Ki-67 增殖指数呈正相关。     

Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?

AIM: The routine tumour grading of invasive ductal carcinoma of the breast has been shown to be a robust determinant of outcome but pathologists have been reluctant to grade lobular cancers. The aim of this study was to determine the prognostic significance of the routine reporting of lobular grade. METHODS: All patients with invasive lobular carcinoma (ILC) treated between 1981 and 1996 were reviewed. Patients with ILC which had been graded were included in the study. These cases were matched with two control patients with invasive ductal carcinoma (IDC) who were operated on in the same year and were closest to the patients in age. Recurrence-free survival was compared with grade for ILC cases and IDC controls using life-table analysis. Similar comparisons were made with the Nottingham Prognostic Index (NPI) between the different prognostic groups. RESULTS: Of 139 cases with ILC, 33 were excluded from the study because 24 were ungraded, five had advanced disease and four had mixed tumours. The mean length of follow-up for ILC cases was 75 months vs 70 months for IDC controls. Recurrence rates for grade I were 10% ILC vs 24% IDC, for grade II 32%vs 32% and for grade III 33%vs 49%. The reported grades for ILC and IDC both showed the expected trend for an increased recurrence rate with more severe tumour grade, but this was only significant for IDC grade II vs grade III (P<0.02) on life-table analysis; only 6% of lobular cancers were reported as grade III. However, there was significant separation of the survival curves when NPI was compared for both lobular and ductal cancers. CONCLUSION: The routine reporting of tumour grade for ILC did not show significant difference in outcome between grade I and grade II, and very few tumours were rated grade III. The validity of grading lobular cancer of the breast requires further evaluation.     

乳腺浸润性导管癌DNA含量与组织学分级的关系

目的探讨DNA含量与乳腺浸润性导管癌组织学分级的关系。方法参照Bloom-Richardson和Elston的方法对72例浸润性导管癌按腺管形成、核的多形性和核分裂像计数进行组织学分级,应用图像分析法检测DNA倍体情况。结果在浸润性导管癌中,Ⅰ级(15例)、Ⅱ级(38例)、Ⅲ级(19例),DI值分别是1.08±0.29、1.37±0.20、2.30±0.53。与乳头状瘤相比,各组间差异具有显著性(P<0.01)。结论在浸润性导管癌中,DNA倍体和组织学分级、临床分期同样可作为较好的预后指标。     

Invasive breast cancer following ductal and lobular carcinoma in situ of the breast

We considered the risk of subsequent invasive breast cancer in a population-based series of 579 carcinomas in situ (CIS) of the breast (482 ductal, 88 lobular) registered between 1977 and 2002 in the Swiss Canton of Vaud. A total of 55 cases of invasive breast cancer were observed vs. 12.3 expected, corresponding to a standardized incidence ratio (SIR) of 4.5 (95% confidence interval [CI], 3.4-5.8). The SIR was 4.6 after ductal and 4.2 after lobular CIS, was similar with passing time since CIS diagnosis, but was higher (SIR = 5.5) for women aged <55 years. At 20 years following CIS, the cumulative risk of invasive breast cancer was 26%, similar for lobular and for ductal CIS. The incidence of invasive breast cancer following CIS showed no consistent pattern of trends with age, all rates in subsequent age groups ranging between 10 and 18 in 1,000. This is compatible with the occurrence of a single mutational event in a population of susceptible women.     

Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women

Adult height and body weight are positively associated with breast cancer risk after menopause, but few studies have investigated these factors according to molecular breast cancer subtype. A total of 18,562 postmenopausal Norwegian women who were born between 1886 and 1928 were followed up for breast cancer incidence from the time (between 1963 and 1975) height and weight were measured until 2008. Immunohistochemical and in situ hybridization techniques were used to subtype 734 incident breast cancer cases into Luminal A, Luminal B [human epidermal growth factor receptor 2 (HER2?)], Luminal B (HER2+), HER2 subtype, basal‐like phenotype (BP) and five‐negative phenotype (5NP). We used Cox regression analysis to assess adult height and body mass index (BMI) in relation to risk of these subtypes. We found a positive association of height with risk of Luminal A breast cancer (p_trend, 0.004), but there was no clear association of height with any other subtype. BMI was positively associated with risk of all luminal breast cancer subtypes, including Luminal A (p_trend, 0.002), Luminal B (HER2?) (p_trend, 0.02), Luminal B (HER2+) (p_trend, 0.06), and also for the HER2 subtype (p_trend, 0.04), but BMI was not associated with risk of the BP or 5NP subtypes. Nonetheless, statistical tests for heterogeneity did not provide evidence that associations of height and BMI differed across breast cancer subtypes. This study of breast cancer risk among postmenopausal women suggests that height is positively associated with risk of Luminal A breast cancer. BMI is positively associated with risk of all luminal subtypes and for the HER2 subtype.     

Proliferating cell nuclear antigen and heat shock protein 70 immuno-localization in invasive ductal breast cancer not otherwise specified

A series of 80 female patients undergoing surgeryfor primary breast ductal infiltrating carcinoma not otherwisespecified (NOS) was immunohistochemically studied in order toverify any relationships between Proliferating Cell Nulear Antigen(PCNA) immunostaining, Heat Shock Protein 70 (HSP70) immunoreactivity,and several clinicopathological predictors.Positive PCNA scores (> 20% of strongly immunopositivemalignant nuclei) were observed in neoplastic cells' nucleiin 13 tumors (16.25%) and were intimately associatedwith axillary nodal involvement (p=0.0131), relativelyhigh tumor grades (p=0.0016), increased tumorsize (p=0.0312), and low or negativelevels of estrogen receptors (p=0.0323). HSP70positive immunoexpression in malignant cells' cytoplasm (percentage ofHSP70 immunoreactive cells > 10%) was detected in33 samples (41.25%). It correlated significantly with presenceof axillary lymph nodal metastases (p=0.0033)and rather poor tumor differentiation (p=0.0014),whereas an association of borderline statistical significance emergedbetween HSP70 immunoreactivity and high progesterone receptor status(p=0.0637).PCNA positive immunostaining demonstrates the tumors' proliferative fractionand might be used as an indicator ofincreased malignant potential in breast cancer since itwas associated with four adverse prognosticators. HSP70 immunodetectionis a probable marker of the biological stressexperienced by breast cancer cells, since it wasrelated to relatively high tumor grades. Since bothproteins may potentially predict disease outcome, their prognosticsignificance must be validated by direct relation tosurvival. A multivariate statistical analysis including the variableswith which both proteins were associated will revealany possible independent prognostic value of PCNA andHSP70 immunostaining in local, ductal invasive breast cancerNOS.     

乳腺癌分子分型的临床意义

目的 利用乳腺癌的3种分子标志物的检测结果将乳腺癌简易分为4种分子亚型,并探讨这4种分子亚型的临床特征及影响预后的因素.方法 依据雌激素受体（ER）、孕激素受体（PR）及人表皮生长因子受体2（HER-2）的免疫组织化学检测结果,采用回顾性方法将本院510例乳腺癌患者分为luminal A、luminal B、HER-2（＋）及basal-like 4种类型.对各型的临床特征采用SPSS13.0 统计软件进行分析,并用Kaplan-Meier法和Cox回归分析各型患者的生存情况及预后因素.结果 在510例乳腺癌患者中,luminal A型、luminal B型、HER-2（＋）型及basal-like型分别占56.86%（290/510）、9.02%（46/510）、3.53%（18/510）和30.59%（156/510）.中位随访66个月,luminal A型、luminal B型、HER-2（＋）型及basal-like型患者的5年总生存率分别为96.21%（279/290）、97.83%（45/46）、83.33%（15/18）和78.85%（123/156）,5年无瘤生存率分别为88.62%（257/290）、95.65%（44/46）、83.33%（15/18）和72.44%（113/156）.basal-like型与luminal A、luminal B型相比,患者无瘤生存率及总生存率较低（P〈0.05）;HER-2（＋）型患者的总生存率比luminal A型患者低（P〈0.05）.经Cox多因素预后分析发现淋巴结状况及分子分型是影响乳腺癌预后的重要因素,淋巴结阳性患者的预后较淋巴结阴性患者差,luminal A型、luminal B型、HER-2（＋）型及basal-like型患者的预后依次变差（P=0.00）.结论 不同分子亚型的乳腺癌患者表现不同的临床特征及预后.淋巴结状况及分子类型是影响乳腺癌患者预后的重要因素,淋巴结阳性及basal-like型患者预后最差.     

淋巴结转移情况不同的乳腺浸润性导管癌病理预后因素对比分析--介绍体视学参数在乳腺浸润性导管癌预后中的应用

目的　对比分析淋巴结转移情况不同的乳腺浸润性导管癌病理预后因素。探讨其体视学参数对判断预后的价值。方法　根据体视学原理 ,采用模板法 ,测定淋巴结阳性 13 7例和阴性 2 0 6例病例的癌实质体积密度 (Vv)及癌巢的表面积密度 (Sv) ;以Bloom Richardson和Elston分级法进行组织学分级。比较淋巴结情况不同时Sv、Vv及组织学分级与预后的关系。结果　无论淋巴结情况及组织学分级如何 ,Sv与预后负相关 ,Vv与预后正相关。癌巢表面积密度Sv≤ 4.4患者 89.3 %生存 5年以上 ,称安全型 ,Sv >5 .5患者 82 .5 %死于 5年以内 ,称危险型。此外 ,Sv <1.8患者 ,均生存5年以上 ,Sv >9.4患者均死于 5年以内。淋巴结阳性组的Sv值高于阴性组 (P <0 .0 1)。此结果Sv正判率 (CA ) 89.2 6%、灵敏度 (SE) 0 .92 5 0、特异度 (SP) 0 .82 93。结论　癌肿生长方式的体视学参数 -Sv值可作为独立判断预后的指标。高Sv值与淋巴结转移关系密切 ,高Sv值同时淋巴结阳性是 5年内死亡的高危因素 ,而Vv、淋巴结转移、组织学分级是乳腺浸润性导管癌预后的相关因素     

The classification of invasive carcinoma of the breast

The classification of invasive breast carcinoma assists diagnosis, allows for comparison of different patient groups in clinical trials and facilitates epidemiological analysis. For the individual patient, accurate tumor classification informs clinical decision-making with emphasis on assessment of prognosis and treatment formulation. Tumor grade is an independent prognostic indicator and is calculated by assessing specific tumor characteristics microscopically. The Tumor Node Metastasis staging system, produced by the American Joint Committee on Cancer Union for International Cancer Control, combines information about the primary tumor size, the status of the regional lymph nodes and the presence or absence of distant metastases at diagnosis to classify disease. In recent years, the use of gene expression profiling technology has led to the development of the molecular classification of breast cancer and has highlighted the importance of hormone receptor and HER2 oncogenic pathways, with particular reference to targeted chemotherapy. Tumor typing involves the identification of ‘no special type’ carcinoma with variable clinical, histological and molecular characteristics and ‘special type’ carcinomas that are usually associated with a particular set of prognostic and predictive indices. Some special type carcinomas have unique biological features that influence diagnostic investigation and clinical management.     

Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer

We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a proliferation marker was verified immunohistochemically (n=44) in invasive ductal breast cancer. In follow-up analyses of the sample of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding urges further prognostic studies with a large sample of patients.     

乳腺浸润性导管癌的超声特征及其与分子分型的相关性

目的:研究乳腺浸润性导管癌的超声表现特征,分析其与临床病理参数的关系。方法:回顾分析我院2014年1月至2018年12月乳腺外科收治的110例乳腺浸润性导管癌患者临床资料。按照不同分子亚型分为Luminal 型、HER-2 过表达型及TN 型。观察不同亚型乳腺浸润性导管癌患者的超声征象并对比分析。结果:彩色多普勒超声检测显示,乳腺浸润性导管癌病例肿块多呈现为形态不规则、边缘毛刺、垂直生长,以内部回声无变化、无微钙化发生、血流分级2级、淋巴结转移、弹性评分≥3分为主。乳腺浸润性导管癌不同分子分型中超声征象形态、边缘、方位、内部回声、微钙化、血流分级、弹性评分组间差异具有统计学意义（P＜0.05）,淋巴结转移与否差异无统计学意义（P＞0.05）。Luminal 型多见于形态不规则、边缘毛刺、垂直生长;TN型多见于形态规则、边缘光整、平行生长;HER-2过表达型多肿块内部微钙化、弹性评分≥3分。不同分子分型组间两两比较,Luminal型和TN型超声征象边缘、方位组间具有统计学差异（P＜0.012 8）;HER-2型和TN型超声征象边缘组间具有统计学差异（P＜0.012 8）;Luminal型和HER-2型超声征象内部回声、微钙化及弹性评分组间具有统计学差异（P＜0.012 8）。结论:乳腺癌超声特征与其分子分型存在一定关系,超声特征可为其分子分型提供一定参考信息。